569 related articles for article (PubMed ID: 35122035)
41. Refining Cancer Management Using Integrated Liquid Biopsy.
Qiu J; Xu J; Zhang K; Gu W; Nie L; Wang G; Luo Y
Theranostics; 2020; 10(5):2374-2384. PubMed ID: 32089746
[TBL] [Abstract][Full Text] [Related]
42. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
43. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.
El Achi H; Khoury JD; Loghavi S
Curr Hematol Malig Rep; 2019 Oct; 14(5):358-367. PubMed ID: 31346903
[TBL] [Abstract][Full Text] [Related]
44. Liquid biopsy for cancer screening, diagnosis, and treatment.
Smania MA
J Am Assoc Nurse Pract; 2020 Jan; 32(1):5-7. PubMed ID: 31913212
[TBL] [Abstract][Full Text] [Related]
45. A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance.
Nicolazzo C; Gazzaniga P
Methods Mol Biol; 2022; 2535():93-104. PubMed ID: 35867225
[TBL] [Abstract][Full Text] [Related]
46. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
47. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
48. Recent technologies enhancing the clinical utility of circulating tumor DNA.
Manoharan A; Sambandam R; Bhat V
Clin Chim Acta; 2020 Nov; 510():498-506. PubMed ID: 32795543
[TBL] [Abstract][Full Text] [Related]
49. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
50. The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer.
Davidson BA; Croessmann S; Park BH
Br J Cancer; 2021 Sep; 125(6):780-788. PubMed ID: 34040179
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
52. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.
Sivapalan L; Murray JC; Canzoniero JV; Landon B; Jackson J; Scott S; Lam V; Levy BP; Sausen M; Anagnostou V
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657818
[TBL] [Abstract][Full Text] [Related]
53. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
[TBL] [Abstract][Full Text] [Related]
54. Potential clinical utility of liquid biopsies in ovarian cancer.
Zhu JW; Charkhchi P; Akbari MR
Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
[TBL] [Abstract][Full Text] [Related]
55. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
Abbou SD; Shulman DS; DuBois SG; Crompton BD
Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
[TBL] [Abstract][Full Text] [Related]
56. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients.
Huang RSP; Xiao J; Pavlick DC; Guo C; Yang L; Jin DX; Fendler B; Severson E; Killian JK; Hiemenz M; Duncan D; Lin DI; Dennis L; Aiyer A; Gjoerup O; Oxnard G; Venstrom J; Elvin J; Ramkissoon SH; Ross JS
Clin Chem; 2021 Nov; 67(11):1554-1566. PubMed ID: 34626187
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer.
Roy D; Tiirikainen M
Trends Cancer; 2020 Feb; 6(2):78-81. PubMed ID: 32061307
[TBL] [Abstract][Full Text] [Related]
58. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
59. Clinical Interest of Circulating Tumor DNA in Oncology.
Franczak C; Filhine-Tressarieu P; Broséus J; Gilson P; Merlin JL; Harlé A
Arch Med Res; 2018 Jul; 49(5):297-305. PubMed ID: 30414710
[TBL] [Abstract][Full Text] [Related]
60. Liquid biopsy of circulating tumor DNA and biosensor applications.
Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
